By Dennis ThompsonHealthDay Reporter
WEDNESDAY, June 27, 2018 (HealthDay News) -- Men with localized high-risk prostate cancer can slow its spread by using a cancer drug that's already on the market, a new clinical trial shows.
The targeted drug enzalutamide (Xtandi) reduced by 71 percent these men's risk of either dying from their prostate cancer or having the cancer spread to other organs, compared against a placebo. The drug also delayed their prostate cancer's reappearance by nearly two years, the researchers said.
Enzalutamide works by blocking the ability of male hormones, or androgens, to fuel the growth of prostate cancer cells. It currently is used to treat men whose cancer has spread beyond the prostate and is no longer responding to "castration" drugs that shut down the body's production of testosterone.